Page last updated: 2024-09-04

atrasentan and cobalt

atrasentan has been researched along with cobalt in 1 studies

Compound Research Comparison

Studies (atrasentan)	Trials (atrasentan)	Recent Studies (post-2010) (atrasentan)	Studies (cobalt)	Trials (cobalt)	Recent Studies (post-2010) (cobalt)
358	41	108	21,222	165	6,525

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Fischgräbe, J; Götte, M; Kersting, C; Kiesel, L; Smollich, M; Wülfing, P	1

Other Studies

1 other study(ies) available for atrasentan and cobalt

Article	Year
Selective ETAR antagonist atrasentan inhibits hypoxia-induced breast cancer cell invasion. Breast cancer research and treatment, 2008, Volume: 108, Issue:2 Topics: Antineoplastic Agents; Aspartic Acid Endopeptidases; Atrasentan; Breast Neoplasms; Cell Hypoxia; Cell Line, Tumor; Cell Movement; Cobalt; Endothelin A Receptor Antagonists; Endothelin-1; Endothelin-Converting Enzymes; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Metalloendopeptidases; Neoplasm Invasiveness; Neoplasm Staging; Pyrrolidines; Receptor, Endothelin A; Time Factors; Up-Regulation	2008

Article

Year

Selective ETAR antagonist atrasentan inhibits hypoxia-induced breast cancer cell invasion.

Breast cancer research and treatment, 2008, Volume: 108, Issue:2

Topics: Antineoplastic Agents; Aspartic Acid Endopeptidases; Atrasentan; Breast Neoplasms; Cell Hypoxia; Cell Line, Tumor; Cell Movement; Cobalt; Endothelin A Receptor Antagonists; Endothelin-1; Endothelin-Converting Enzymes; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Metalloendopeptidases; Neoplasm Invasiveness; Neoplasm Staging; Pyrrolidines; Receptor, Endothelin A; Time Factors; Up-Regulation

2008